| 1 |
34728569 | Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas. | 2022 Jan |
1 |
| 2 |
34767916 | Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance. | 2022 Jan |
2 |
| 3 |
35443722 | Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis. | 2022 Apr 20 |
1 |
| 4 |
35443750 | The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA. | 2022 Apr 20 |
1 |
| 5 |
32165486 | The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia. | 2021 May 1 |
1 |
| 6 |
34331013 | Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss. | 2021 Sep |
1 |
| 7 |
32066201 | Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma. | 2020 May |
1 |
| 8 |
32184020 | Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells. | 2020 May 14 |
1 |
| 9 |
30008477 | The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells. | 2019 Jan |
2 |
| 10 |
31115744 | Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo. | 2019 Jun |
1 |
| 11 |
31320594 | Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. | 2019 Nov 15 |
2 |
| 12 |
31515455 | Improving Response to FLT3 Inhibitors-BCL2 the Rescue? | 2019 Nov 15 |
1 |
| 13 |
29559471 | Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells. | 2018 Jun 1 |
2 |
| 14 |
29761903 | The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation. | 2018 May 15 |
1 |
| 15 |
30021909 | Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. | 2018 Nov 1 |
1 |
| 16 |
30185627 | A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. | 2018 Dec |
1 |
| 17 |
30701031 | Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells. | 2018 Dec 28 |
1 |
| 18 |
28578655 | Potential mechanisms of resistance to venetoclax and strategies to circumvent it. | 2017 Jun 2 |
1 |
| 19 |
28847998 | Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. | 2017 Nov 30 |
1 |
| 20 |
29018077 | Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. | 2017 Nov 30 |
1 |
| 21 |
29263915 | Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. | 2017 |
1 |
| 22 |
26939706 | Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. | 2016 May |
3 |
| 23 |
27056887 | High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition. | 2016 May 10 |
3 |
| 24 |
27095788 | BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. | 2016 Jun 23 |
1 |
| 25 |
26565405 | Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). | 2015 Nov 13 |
1 |